Annovis Bio and NIA Enter into Cooperative Research and Development Agreement

Annovis Bio, Inc. has announced a Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging (NIA), a subsect of the National Institutes of Health.  This CRADA will support a collaboration between NIA and Annovis as they develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived extracellular vesicles (EV) containing potential biomarkers of neuronal function and viability.

Annovis Bio is a clinical-stage drug platform tackling neurodegenerative diseases including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Buntanetap is their lead candidate and simultaneously inhibits the production of multiple neurotoxic brain proteins including amyloid precursor protein (APP), Tau and α-Synuclein. These proteins have been seen to impair axonal transport leading to cell death. 

Annovis Bio’s buntanetap sets itself apart from other AD drugs in development by inhibiting the proteins before they can even form. These other drugs in development typically attempt to remove an already formed protein.

The collaboration aims to validate the pharmacodynamic biomarkers by comparing the abundance of the biomarker in EVs isolated from blood and cerebrospinal fluid with the change in biomarker levels after a buntanetap dose. Biomarkers will be assessed in de-identified plasma and CSF samples of Alzheimer’s Disease (AD), Parkinson’s disease (PD), and control participants from Annovis’ Phase 2a clinical trials.

Neurodegenerative diseases are a truly unmet medical need. Annovis Bio’s novel approach to addressing neurodegeneration offers a new method with potential to reverse the toxic cascade caused by neurotoxic proteins. By preventing impaired axonal transport, nerve cell death can be prevented before it is even begun.

Are you developing new clinical pharmaceuticals? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts